BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes medicines for patients with genetic diseases and cancers with clear genetic drivers. The company operates a decentralized hub-and-spoke model to advance multiple programs concurrently, focusing on rare and genetically defined conditions. Its approved products include acoramidis, marketed as Attruby in the United States and Beyonttra internationally for transthyretin amyloid cardiomyopathy, and fosdenopterin, marketed as Nulibry for molybdenum cofactor deficiency. BridgeBio is advancing late-stage clinical programs for infigratinib, BBP-418, and encaleret, targeting conditions such as achondroplasia, limb-girdle muscular dystrophy type 2I/R9, and autosomal dominant hypocalcemia type 1. The company collaborates with partners including Bayer in Europe and Alexion in Japan for the commercialization of acoramidis outside the United States. BridgeBio also maintains minority equity interests in GondolaBio and BridgeBio Oncology Therapeutics, which focus on early-stage research for RAS and PI3Kα-driven cancers. Founded ten years ago, the company has generated numerous investigational new drug applications and peer-reviewed publications while treating thousands of patients with its approved therapies.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage bridgebio.com
Sector Healthcare IR page investor.bridgebio.com/overview/default.aspx
Tags
genetic diseases, rare diseases, small molecule inhibitors, transthyretin amyloidosis, muscular dystrophy, hypocalcemia, cholangiocarcinoma, ras inhibitors, pi3k inhibitors, biopharmaceuticals, Attruby, Beyonttra, Nulibry, Truseltiq, acoramidis, fosdenopterin, infigratinib, BBP-418, encaleret, BBP-812, GondolaBio, BridgeBio Oncology Therapeutics
Press page —

Metrics

Valuation  
Market cap $ 14.279B
Market cap (USD) $ 14.279B
P/E -23.96
PEG —
P/BV -8.59
P/S 15.10
P/OCF -38.70
P/FCF -38.61
Dividend yield —
Turnover / mcap —
Returns  
ROE 35.1%
ROI —
ROIC —
Profit margin -146.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 144
Quality score -37.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 502.076M 221.902M 9.303M 77.648M 69.716M 8.249M 40.56M —
Net profit -732.938M -543.347M -653.251M -484.652M -586.454M -505.488M -288.585M -169.451M
Free cash flow -447.007M -521.659M -529.026M -424.315M -511.18M -407.232M -256.225M -138.821M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 76.49 27.44 40.37 7.62 16.68 71.11 35.05 —
Price performance 12m 1.79 -0.32 4.3 -0.54 -0.77 1.03 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — 1.75M 4.72M 139M
↳ YoY growth +169.7% +2,853.1%
Borrowings, current (USD) — — — 1.46M — — — — —
Borrowings, non-current (USD) — 54.5M 91.8M 92.4M 431M 431M 446M 437M —
Lease liabilities (USD) — — 8M 20.2M 23.9M 15.9M 13.1M 9.2M 10M
Cash and deposits (USD) 92M 239M 364M 356M 394M 377M 376M 681M 570M
Intangible assets (USD) — — — 0.00 44.9M 28.7M 26.3M 23.9M 28.1M
Right-of-use assets (USD) — — 10M 16.5M 15.9M 10.7M 8.03M 5.77M 8.15M
Net debt (borrowings + leases - cash) (USD) — -382M -264M -242M 60.9M 70.3M 83.6M -235M —
Cash flow detail
Operating cash flow (USD) -40.5M -137M -254M -400M -498M -419M -528M -521M -446M
Purchases of property, plant and equipment (USD) -464,000 -2.18M -2.64M -7.52M -13.2M -4.82M -1.31M -933,000 -1.1M
Purchases of intangible assets (USD) — — — 0.00 -35M -1.5M 0.00 -7.98M -8.5M
Change in receivables (cash effect) (USD) — — — — — 15.2M 15.3M -2.97M -135M
Change in inventories (cash effect) (USD) — — — — — — 0.00 0.00 -25.3M
Change in payables (cash effect) (USD) 1.58M 16.7M -4.66M -735,000 2.83M -349,000 2.78M 1.51M 26.6M
Dividends paid (cash effect) (USD) -1.15M — -997,000 — — — — — —
Share buybacks (cash effect) (USD) — — — -75M -200M 0.00 0.00 0.00 -48.3M
Interest paid (cash effect) (USD) — -1.57M -6.09M -15.3M -29.8M -54.4M -61.1M -91.3M -43.7M
Income taxes paid (cash effect) (USD) — — — — — — 0.00 0.00 -1.2M
Share-based compensation (USD) 1.84M 6.07M 21.4M 58.5M 99.5M 91.6M 109M 95.8M 133M
Operating cash flow before change in receivables (USD) — — — — — -435M -543M -518M -311M
Free cash flow (OCF - PPE - intangibles) (USD) -41M -139M -256M -407M -546M -426M -529M -530M -456M
Income detail
Research and development expense (USD) 30.6M 140M 210M 337M 451M 399M 456M 506M 452M
↳ 5y CAGR +67.2% +26.6% +19.3% +6.0%
Total comprehensive income (USD) -43.8M -169M -288M -506M -587M -485M -653M -543M -733M
Comprehensive income to owners (USD) -30.6M -131M -260M -449M -563M -481M -643M -536M -725M
Reported Mar 3, 2020 Mar 3, 2020 Mar 3, 2020 Feb 23, 2023 Feb 25, 2022 Feb 20, 2025 Feb 24, 2026 Feb 24, 2026 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 6, 2026

PALO ALTO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on November 5, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 80 new employees in restricted stock units for an aggregate of 147,578 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn , X , Facebook , Instagram , YouTube , and TikTok .

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
[email protected]   
(650)-789-8220

BridgeBio Investor Contact:
Investor Relations
[email protected]   

Primary Logo

Source: BridgeBio Pharma, Inc.

View All News

Stay Informed.

COMPANY

INSIGHTS

SCIENCE

MEDICINES & PIPELINE

PATIENTS

SOCIAL

Bridgebio Logo

This site is intended for U.S. residents.

BridgeBio, Attruby, the Attruby logo, ForgingBridges, and the ForgingBridges logo are trademarks of BridgeBio Pharma, Inc. All other trademarks are property of their respective owners.

© 2026 BridgeBio Pharma Inc. - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

November 3, 2026

PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two moderated posters and three posters on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM), along with one BridgeBio-supported poster presentation led by Abbott Laboratories, will be shared at the American Heart Association (AHA) Scientific Sessions 2026, taking place in Chicago, Illinois on November 6-9, 2026. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

Acoramidis is approved as Attruby® by the U.S. FDA and is approved as BEYONTTRA® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, the Brazilian Health Regulatory Agency (ANVISA), and the Australian Therapeutic Goods Administration (TGA) with all labels specifying near-complete stabilization of TTR.

Moderated Posters:
Bridging the Diagnostic Gap in Transthyretin Cardiac Amyloidosis (ATTR-CM): Enhancing ATTR-CM Detection at the Time of Heart Failure Diagnosis in Women Through Sex-Specific ATTR Models (SS-ATTR-CMs)
Presenter: Hyewon Jeong, M.D., M.S., Massachusetts Institute of Technology, U.S.
Date/time: Monday, November 9 at 9:50 am CT

Artificial Intelligence for the Screening of ATTR Cardiomyopathy in the U.S.: A Multicenter Analysis from the TRACE-AI Network
Presenter: Bruno Batinica, MBChB, Yale School of Medicine, U.S.
Date/time: Monday, November 9 at 11:20 am CT

Posters:
Effects of Acoramidis on Heart Failure Events in Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM
Presenter: Mazen Hanna, M.D., Cleveland Clinic, U.S.
Date/time: Sunday, November 8 at 3:15 pm CT

Risk of Multiple Cardiovascular-Related Hospitalizations and of All-Cause Mortality in Transthyretin Amyloid Cardiomyopathy: Findings from ATTRibute-CM Using Multistate Modeling
Presenter: Justin L. Grodin, M.D., UT Southwestern Medical Center, U.S.
Date/time: Sunday, November 8 at 3:15 pm CT

Recovery After Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights from an N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Analysis of the ATTRibute-CM Study
Presenter: Prem Soman, M.D., University of Pittsburgh Medical Center, U.S.
Date/time: Sunday, November 8 at 3:15 pm CT

Abbott Laboratories-Led, BridgeBio-Supported Poster Presentation:
Detection of Tetrameric Transthyretin by ARCHITECT c and Alinity c Assays
Presenter: Lici A. Schurig Briccio, Ph.D., Abbott Laboratories, U.S.
Date/time: Monday, November 9 at 9:36 am CT

About Attruby® (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
[email protected]

(650) 789-8220

BridgeBio Investor Contact:
BridgeBio Investor Relations
[email protected]

Primary Logo

Source: BridgeBio Pharma, Inc.

View All News

Stay Informed.

COMPANY

INSIGHTS

SCIENCE

MEDICINES & PIPELINE

PATIENTS

SOCIAL

Bridgebio Logo

This site is intended for U.S. residents.

BridgeBio, Attruby, the Attruby logo, ForgingBridges, and the ForgingBridges logo are trademarks of BridgeBio Pharma, Inc. All other trademarks are property of their respective owners.

© 2026 BridgeBio Pharma Inc. - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

On October 29, 2026, BridgeBio Pharma, Inc. (the “Company”) reported recent business updates and its financial results for the third quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Prompts

BridgeBio Pharma, Inc. (ticker BBIO), listed in United States.

ETFs Holding BridgeBio Pharma, Inc.

ETF Weight in ETF Shares Market value As of
HELX 3.50% 13,129 $ 977.848K Jun 30, 2026
HRTS 3.18% 23,113 $ 1.77M Aug 31, 2026
CANC 2.33% 64,261 $ 4.922M Aug 31, 2026
FSML 1.32% 22,242 $ 1.657M Jun 30, 2026
SSMG 1.19% 473 $ 37.883K Jul 31, 2026
ILDR 1.10% 45,229 $ 3.499M Nov 16, 2026
SEIS 1.01% 78,806 $ 5.869M Jun 30, 2026
GDOC 0.95% 2,421 $ 185.424K Aug 31, 2026
GSC 0.83% 30,091 $ 2.305M Aug 31, 2026
JDOC 0.64% 822 $ 63.13K Nov 17, 2026
PSC 0.60% 188,692 $ 14.054M Jun 30, 2026
ORR 0.52% 24,917 $ 1.91M Nov 18, 2026
MKTN 0.49% 7,088 $ 527.914K Jun 30, 2026
RUSC 0.43% 4,615 $ 343.725K Jun 30, 2026
FSCC 0.42% 20,124 $ 1.541M Aug 31, 2026
FESM 0.27% 208,816 $ 15.553M Jun 30, 2026
SCDS 0.25% 298 $ 22.886K Nov 17, 2026
FFF 0.23% 220 $ 14.476K Sep 30, 2026
TMSL 0.20% 73,088 $ 5.444M Jun 30, 2026
AVIE 0.12% 254 $ 19.649K Nov 16, 2026
FSEG 0.10% 79 $ 5,883.92 Jun 30, 2026
JGRO 0.10% 122,335 $ 9.395M Nov 17, 2026
REMC 0.09% 40 $ 2,979.20 Jun 30, 2026
MSSM 0.07% 6,923 $ 530.233K Aug 31, 2026
VFMO 0.06% 14,452 $ 1.107M Aug 31, 2026
IALT 0.03% 26,457 $ 2.047M Nov 16, 2026
JSTC 0.03% 1,314 $ 101.651K Nov 17, 2026
AVUQ 0.02% 974 $ 75.349K Nov 16, 2026
DCOR 0.02% 94,752 $ 7.407M Nov 12, 2026
AVLC 0.01% 2,642 $ 204.385K Nov 16, 2026
DFAC 0.01% 89,848 $ 7.023M Nov 12, 2026
DFUS 0.00% 7,355 $ 574.94K Nov 12, 2026
DFAU 0.00% 1,926 $ 150.555K Nov 12, 2026
NTRL short 0.00% -379 $ 0.00 Nov 16, 2026